The recombinant human thyroid-stimulating hormone (rhTSH) can be used for differentiated thyroid cancer (DTC) preparation before ¹³¹I therapy, and follow-up. Since its approval by the American Food and Drug Administration (FDA) in 1998, rhTSH has been clinically used in European countries, the United States, and other countries for nearly 30 years. In April 2024, China’s first independently developed rhTSH agent was approved. Based on clinical experience and evidence from domestic and international studies, an expert consensus on the application of rhTSH has been developed following thorough consultations among experts. The consensus offers evidence-based recommendations to guide the appropriate use of rhTSH in clinical practice.

Objective:To investigate the predictive value of preoperative 18F-FDG PET/CT imaging for postoperative recurrence and metastasis in patients with stage Ⅰ solid and subsolid non-small cell lung cancer (NSCLC). Methods:This retrospective analysis included 139 patients (71 males, 68 females; age (62.1±9.0) years) with ⅠA1-ⅠB stage solid and subsolid NSCLC who underwent surgery and preoperative 18F-FDG PET/CT imaging at the Fourth Hospital of Hebei Medical University from December 2020 to December 2022. Patients were randomly divided into a training group and a validation group in a ratio of 7∶3, and SUV max, metabolic tumor volume (MTV), total lesion glycolysis (TLG), clinical data, and disease-free survival (DFS) were collected. ROC curves were generated for the training group to determine the optimal cut-off values of SUV max, MTV, and TLG for predicting recurrence and metastasis. The Cox proportional hazards regression model was used to identify factors predicting DFS and to establish a prediction model, which was then validated in the validation group. The prognostic efficacy of the model was evaluated by using the concordance index (C-index). Results:Of 139 patients, 97 were in the training group and 42 were in the validation group, with 23 experienced recurrences during the follow-up period, including 18 in the training group and 5 in the validation group. The optimal cut-off values of SUV max, MTV and TLG for predicting tumor recurrence and metastasis in the training group were 5.85, 5.55cm 3, and 12.55g, respectively. Univariate analysis showed that SUV max (hazard ratio ( HR)=4.83, 95% CI: 1.81-12.89, P=0.002), MTV ( HR=6.90, 95% CI: 2.27-20.98, P<0.001), and TLG ( HR=5.77, 95% CI: 1.90-17.57, P=0.002) were predictive factors for postoperative recurrence and metastasis, while multivariate analysis identified MTV ( HR=4.67, 95% CI: 1.42-15.36, P=0.011) as an independent predictive factor. The prognostic C-index (95% CI) of models in training group and validation group were 0.814(0.745-0.882) and 0.810(0.624-0.995). Conclusions:Preoperative 18F-FDG PET/CT imaging has significant predictive value for postoperative recurrence and metastasis risk in patients with stage Ⅰ solid and subsolid NSCLC. MTV can be considered as an independent prognostic factor for preoperative recurrence and metastasis.

Objective:To investigate the predictive value of preoperative 18F-FDG PET/CT imaging for postoperative recurrence and metastasis in patients with stage Ⅰ solid and subsolid non-small cell lung cancer (NSCLC). Methods:This retrospective analysis included 139 patients (71 males, 68 females; age (62.1±9.0) years) with ⅠA1-ⅠB stage solid and subsolid NSCLC who underwent surgery and preoperative 18F-FDG PET/CT imaging at the Fourth Hospital of Hebei Medical University from December 2020 to December 2022. Patients were randomly divided into a training group and a validation group in a ratio of 7∶3, and SUV max, metabolic tumor volume (MTV), total lesion glycolysis (TLG), clinical data, and disease-free survival (DFS) were collected. ROC curves were generated for the training group to determine the optimal cut-off values of SUV max, MTV, and TLG for predicting recurrence and metastasis. The Cox proportional hazards regression model was used to identify factors predicting DFS and to establish a prediction model, which was then validated in the validation group. The prognostic efficacy of the model was evaluated by using the concordance index (C-index). Results:Of 139 patients, 97 were in the training group and 42 were in the validation group, with 23 experienced recurrences during the follow-up period, including 18 in the training group and 5 in the validation group. The optimal cut-off values of SUV max, MTV and TLG for predicting tumor recurrence and metastasis in the training group were 5.85, 5.55cm 3, and 12.55g, respectively. Univariate analysis showed that SUV max (hazard ratio ( HR)=4.83, 95% CI: 1.81-12.89, P=0.002), MTV ( HR=6.90, 95% CI: 2.27-20.98, P<0.001), and TLG ( HR=5.77, 95% CI: 1.90-17.57, P=0.002) were predictive factors for postoperative recurrence and metastasis, while multivariate analysis identified MTV ( HR=4.67, 95% CI: 1.42-15.36, P=0.011) as an independent predictive factor. The prognostic C-index (95% CI) of models in training group and validation group were 0.814(0.745-0.882) and 0.810(0.624-0.995). Conclusions:Preoperative 18F-FDG PET/CT imaging has significant predictive value for postoperative recurrence and metastasis risk in patients with stage Ⅰ solid and subsolid NSCLC. MTV can be considered as an independent prognostic factor for preoperative recurrence and metastasis.

Objective : To construct triggering receptor expressed on myeloid cells 2(TREM2) gene knockout(TREM2-/-) mice using CRISPR/Cas9 technology, to breed TREM2-/- mice and to analyze the genotype of TREM2-/- mice. Methods : CRISPR/Cas9 technology was used to selectively knock out exon 2-3 regions of TREM2 gene to construct a TREM2-/- mouse model, and the genetic background of all mice was C57BL/6J. Polymerase chain reaction(PCR) was used to identify the genotype of mice. Quantitative real-time PCR(qPCR) and Western blot were used to detect the expression level of TREM2 in major tissues of mice, and the authenticity and scientific nature of PCR identification results were verified from mRNA level and protein level. According to the sgRNA sequence, the possible off-target sites were predicted on the CCTop website, and the tail DNA of mice was extracted and amplified by PCR and then Sanger sequencing was performed to detect whether there was off-target effect in TREM2-/- mice. Results : TREM2-/- mice were successfully constructed by CRISPR/Cas9 technology, and the mice were genotyped. The results of agarose gel electrophoresis showed that the mouse genotype with only 415 bp band amplified was wild type(WT), the mouse genotype of the 449 bp band amplified only was TREM2-/-, and the mouse genotypes amplified with 415 bp and 449 bp double bands were heterozygous. qPCR results showed that compared with WT mice, the mRNA expression of TREM2 in heart and brain tissues of TREM2-/- mice was down-regulated(P-/- mice was reduced(P-/- mice. Conclusion TREM2-/- mice are successfully constructed and bred, a reliable genotype identification method is established, the genetic stability of the mouse model is verified, which will provide an important genetic animal model for the study of TREM2 gene function.

177Lu-prostate specific membrane antigen(PSMA)radio-ligand therapy has been approved abroad for advanced prostate cancer and has been in several clinical trials in China.Based on domestic clinical practice and experimental data and referred to international experience and viewpoints,the expert group forms a consensus on the clinical application of 177Lu-PSMA radio-ligand therapy in prostate cancer to guide clinical practice.

68Ga-DOTATATE/18F-FDG two-day low-dose total-body PET/CT imaging is increasingly employed to facilitate the diagnosis,prognosis,and heterogeneity assessment of neuroendocrine neoplasms.We present a consensus on operational guideline for a two-day combined imaging from experts in low-dose/ultra-low-dose total-body PET/CT from several domestic medical institutions.

To explore how the joint-teaching mode of tomographic-radiologic anatomy and topographic anatomy in a way of case-based learning (CBL) promotes the education of medical students.

Fibroblast activation protein inhibitors(FAPI)can specifically bind to fibroblast activation protein,which is highly expressed in tumor stroma,and 68Ga-FAPI do not get involved into the procedure of glucose metabolism in tumor cells.68Ga-FAPI PET/CT and PET/MR can be used for displaying malignant tumors at various sites and play a unique role for diagnosis and differential diagnosis.The research progresses of 68 Ga-FAPI-based PET/CT and PET/MR for diagnosing malignant tumors were reviewed in this article.

Objective:To explore the value of the imaging nomogram model based on preoperative CT features of patients with small intestinal stromal tumor (SIST) in predicting pathological risk classification.Methods:This was a cohort study. The patients who were diagnosed as primary SIST by postoperative pathology in Cancer Hospital, Chinese Academy of Medical Sciences from January 2014 to October 2023 were retrospectively included. According to the modified 2008 National Institutes of Health classification criteria, the patients were divided into a pathological intermediate/high-risk group (86 cases) and a very low/low-risk group (56 cases). The features of preoperative enhanced CT images of SIST were analyzed, including tumor boundary, necrosis, intra-tumoral hemorrhage, intra-tumoral calcification, growth pattern, enhancement pattern, enhancement degree, enlarged vessels feeding or draining the mass (EVFDM), and tumor location. Patients were followed up to determine the recurrence-free survival (RFS). Univariate and multivariate logistic regression were used to screen the independent predictors of SIST with pathological medium/high-risk group. The independent predictors were combined to construct an imaging prediction model, and a nomogram was drawn. The receiver operating characteristic curve was used to evaluate the predictive efficacy of the model. The Kaplan-Meier method was used to draw the survival curve, and the log-rank test was used to compare the differences in RFS.Results:Univariate logistic regression results showed that tumor shape, necrosis, intra-tumoral hemorrhage, EVFDM, and tumor location were potentially related to medium/high-risk SIST. Multivariate logistic regression results showed that tumor shape ( OR=3.92, 95% CI 1.58-9.71, P=0.003), necrosis ( OR=4.60, 95% CI 1.91-11.09, P<0.001), and EVFDM ( OR=6.25,95% CI 1.74-22.47, P=0.005) were independent predictors of pathological intermediate/high-risk SIST. The area under the curve of the imaging predictive model combining the three predictors to predict the intermediate/high-risk SIST was 0.835 (95% CI 0.769-0.901), the sensitivity was 0.810, the specificity was 0.839, and the accuracy was 0.789. Taking the cut-off value (0.810) as the boundary value, the patients were divided into the high-risk group (74 cases) and the low-risk group (68 cases) according to the prediction results. The median RFS of the predicted high-risk group was poorer than that of the predicted low-risk group, and the difference was statistically significant ( χ2=5.20, P=0.023). Conclusions:The imaging nomogram model based on preoperative CT image features shape, necrosis, and EVFDM can effectively predict the pathological intermediate/high-risk SIST before surgery and has important predictive value for postoperative recurrence.

Objective:To compare the predictive values of response evaluation criteria in lymphoma (RECIL)2017 and Lugano classification for the prognosis of patients with diffuse large B-cell lymphoma(DLBCL) at the end of treatment.Methods:A total of 107 patients (50 males, 57 females, age (49.3±17.4) years) with DLBCL who underwent PET/CT at the end of chemotherapy in the Fourth Hospital of Hebei Medical University between February 2014 and December 2021 were analyzed retrospectively. The RECIL2017 and Lugano classification were used to evaluate the response. Kaplan-Meier survival analysis was used to evaluate progression-free survival (PFS) and overall survival (OS). The Kappa test was used to evaluate the consistency of the two criteria after chemotherapy, and ROC curve (Delong test)was used to compare the predictive values of the two criteria for PFS and OS. Results:The median follow-up time was 47.5(33.4, 57.5) months. Kaplan-Meier analysis showed that the 5-year PFS rates (74.5%(35/47), 71.4%(15/21), 57.1%(12/21), 4/18; χ2=38.85, P<0.001) and OS rates (89.4%(42/47), 81.0%(17/21), 61.9%(13/21), 7/18; χ2=29.52, P<0.001) in complete metabolic response (CMR), partial metabolic response (PMR), no metabolic response (NMR) and progressive metabolic disease (PMD) groups evaluated by Lugano classification were statistically different, as well as those in complete response (CR), partial response (PR), minor response (MR), stable disease (SD) and progressive disease (PD) groups evaluated by the RECIL2017 (5-year PFS rates: 76.9%(40/52), 8/12, 6/11, 6/12, 30.0%(6/20), χ2=29.05, P<0.001; 5-year OS rates: 90.4%(47/52), 8/12, 6/11, 9/12, 45.0%(9/20), χ2=23.63, P<0.001). The RECIL2017 and Lugano classification had good consistency in the efficacy evaluation of DLBCL patients at the end of chemotherapy (70.1%(75/107); Kappa=0.57, P<0.001). The AUCs of Lugano classification for predicting PFS and OS were 0.730 (95% CI: 0.625-0.834, P<0.001) and 0.908 (95% CI: 0.845-0.970, P<0.001) respectively, and those of RECIL2017 were 0.717 (95% CI: 0.612-0.822, P<0.001) and 0.880 (95% CI: 0.812-0.949, P<0.001). The AUCs of the Lugano classification for PFS and OS were slightly higher than those of RECIL2017, without significant differences ( z values: 0.44, 1.09, both P>0.05) . Conclusion:Both RECIL2017 and Lugano classification can evaluate the prognosis of patients with DLBCL at the end of treatment, and Lugano classification is more accurate.